Phanes Therapeutics reported positive Phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, in combination with chemotherapy as first‑line treatment for CLDN18.2‑positive metastatic pancreatic ductal adenocarcinoma. Data were presented at ASCO‑GI 2026 and show clinical responses supporting further development. The regimen targets the tumor antigen CLDN18.2 while blocking the 'don't eat me' CD47 signal, a two-pronged strategy to enhance antitumor immunity in a hard-to-treat cancer. The company said the combination demonstrated tolerability consistent with expectations and signals of efficacy versus historical controls. If confirmed in randomized trials, the asset could alter first‑line treatment options for a molecularly defined subset of PDAC patients and spur partnerships or regulatory interest.